Citigroup
SLNO

Citigroup’s Soleno Therapeutics SLNO Stock Holding History

Citigroup’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-255,400
Closed -$11.8M – 6360
2025
Q4 		$11.8M Buy
255,400
+223,900
+711% +$12.3M 0.01% 1410
2025
Q3 		$2.13M Buy
+31,500
New +$2.34M ﹤0.01% 2623

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Citigroup's SLNO Position: Q1 2026 in Review

Citigroup increased its Soleno Therapeutics (SLNO) stake by 63% in Q1 2026, buying an estimated $862K and bringing the position to 56,656 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2693.

Citigroup first reported a position in SLNO in Q1 2015 and has held it in 20 quarters since. The position peaked at $4.18M in Q1 2024. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Citigroup held 56,656 shares of Soleno Therapeutics worth $1.9M as of Q1 2026.
  • Citigroup bought 21,993 Soleno Therapeutics shares in Q1 2026, an estimated $862K.
  • Soleno Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2693 holding.
  • Citigroup first reported a position in Soleno Therapeutics in Q1 2015 and has held it in 20 quarters since.
  • Citigroup's Soleno Therapeutics position peaked at $4.18M in Q1 2024.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.